Flower-Shaped Lipid Nanoparticles Evade Apolipoprotein E-Mediated Liver Tropism for Safe and Enhanced Cytokine-Based Cancer Immunotherapy.
Level 5 - mechanism / opinion, no new human data
Preclinical bench and animal study without human data.
PubMed 41042570 · doi:10.1021/acsnano.5c11552
What was done
Researchers developed flower-shaped lipid nanoparticles (RLNPs) by partially replacing native cholesterol with a TLR7/8 agonist-conjugated analogue to alter nanoparticle surface curvature and reduce apolipoprotein E (ApoE) binding. They evaluated intratumoral delivery of IL-12 mRNA using these particles to limit off-target hepatic accumulation and hepatotoxicity. The nanoparticles were further functionalized with a CD47-SIRPα blocking peptide and tested in orthotopic 4T1 breast cancer mouse models, as well as formulated into a photo-cross-linkable hydrogel combined with anti-PD-L1 to assess postoperative delivery and recurrence prevention.
What was found
The abstract reports no numerical values or statistical metrics. Qualitatively, RLNPs constrained ApoE binding via altered surface curvature, sustained tumor transfection, and decreased liver accumulation and IL-12 mRNA-induced hepatotoxicity compared to conventional formulations. Functionalized RLNPs induced M1 macrophage activation, and the hydrogel-based delivery combined with anti-PD-L1 prevented tumor recurrence while maintaining prolonged systemic safety in mice.
Why it matters
ApoE-mediated liver accumulation causes off-target hepatotoxicity that restricts the clinical utility of intratumoral cytokine mRNA delivery. Modifying lipid nanoparticle morphology via cholesterol substitution provides a structural strategy to evade hepatic tropism and improve the safety of localized cancer immunotherapy.
Limits
The abstract provides no numerical data, effect sizes, or animal sample sizes. Findings are limited to hydrodynamic modeling and orthotopic murine tumor models, leaving clinical translatability, pharmacokinetics, and human safety unmeasured.
Cited by
- supports When injected into the body, lipid nanoparticles naturally tend to travel to the liver.